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Abstract
Background: The objective of this study was to investigate factors affecting health-related quality of life (HRQoL)
among Estonian persons with Parkinson’s disease (PD).
Methods: 268 persons with PD were evaluated using: the Movement Disorder Society Unified Parkinson’s Disease
Rating Scale (MDS-UPDRS); the Hoehn and Yahr scale (HY); the Schwab and England Activities of Daily Living scale
(SE-ADL); the Beck Depression Inventory (BDI); the Mini Mental State Examination (MMSE); the Parkinson’s Disease
Questionnaire (PDQ-39). Additional questions on clinical and socio-demographic variables were asked during a
semi-structured interview. Predictors of HRQoL were tested using multiple regression analysis.
Results: The main predictors of low HRQoL were depression and motor and non-motor aspects of daily living.
59.9 % of the variation in the PDQ-39 summary index (SI) score was explained by the predictive variables identified
in this study. None of the socio-demographic variables (age, gender, urban/rural living, marital status, living alone/
with others, education level) were significant predictors of HRQoL. Prevalence of non-motor Parkinson’s symptoms
were high (99.6 %); cognitive impairment, sleep and urinary problems were the most common. All non-motor
symptoms correlated significantly with low HRQoL, except the features of impulse control disorders (ICDs).
Conclusions: Depression and motor and non-motor daily living experiences were found to be significant and
independent factors of low HRQoL in persons with PD. Depression was the strongest determinant of low
HRQoL. Our results highlight the importance of recognition and management of non-motor symptoms, as
these features had more impact on patients’ HRQoL than clinically assessed motor symptoms.
Keywords: Depression, Health-related quality of life, Impulse control disorders, MDS-UPDRS, Non-motor
symptoms, Multiple regression analysis, Parkinson’s disease, PDQ-39
Background
Parkinson’s disease (PD) is one of the most common
neurodegenerative diseases worldwide, with a prevalence
ranging from 31–201 per 100,000 population [1]. The
symptoms of PD encompass motor features such as ri-
gidity, bradykinesia, tremor and postural instability [2],
and non-motor symptoms including impairment of
olfaction, vision, sleep, salivation, gastric and bowel
function, sebaceous gland activity, and mood and cogni-
tion [3]. PD diagnosis is based upon the presence of a
set of cardinal motor signs; progression is defined by the
degree of motor disability; management is primarily di-
rected towards improving motor symptoms [2, 4].
Persons with PD are particularly vulnerable to deteri-
oration of health-related quality of life (HRQoL) result-
ing from significant motor disability and the burden of
non-motor symptoms. Assessment of HRQoL of persons
with PD is thus of essential importance. Several factors
have been reported to be associated with low HRQoL.
Among motor symptoms, the most significant determi-
nants affecting HRQoL are disease severity, motor com-
plications, postural instability and gait disorder [5–7].
Among non-motor symptoms, depression, anxiety,
cognitive impairment, fatigue, pain, urinary distur-
bances and sleep problems were found to be the most
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significant determinants of HRQoL [5, 8, 9]. Among other
factors, a high levodopa equivalent daily dose and comor-
bidities were found to be prevalent and independent
determinants of HRQoL [6]. Parallel to the clinical
features, several socio-demographic factors such as
level of education and number of people in a house-
hold have been described as independent determinants of
HRQoL [5, 7].
Most previous studies however have assessed only a
limited number of factors in relation to HRQoL. The im-
pact of certain variables (e.g. rural living, marital status,
education, comorbidities) have been infrequently sys-
tematically studied. The main aim of our study therefore
was to evaluate the impact of a wide range of socio-
demographic and clinical factors upon the HRQoL of a
cohort of persons with PD in Estonia. We also focused
on the non-motor symptoms identified by the new
version of the Movement Disorder Society Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS) Part I,
which has recently been adopted and validated [10].
Methods
Participants
A total of 268 persons with PD were recruited for a
community-based study by the Department of Neurology
and Neurosurgery of Tartu University Hospital, which is
one of two regional hospitals in Estonia. The study was
based on a PD cohort derived from an epidemiological
study primarily aimed at investigating the epidemiology,
clinical characteristics and treatment of PD in Estonia. The
current study was conducted in the city and district of
Tartu between October 2010 and May 2013. Patient selec-
tion was made via evaluation of information from hospital
records, neurologists and general practitioners, nursing
homes, the local PD Society, and the database of the
Estonian Health Insurance Fund. Only patients who
fulfilled the Queen Square Brain Bank Criteria [2, 11]
were included in the study. As this was an epidemio-
logical study, all patients with a confirmed PD diagnosis
were enrolled, and no specific exclusion criteria were set.
The study was approved by the Research Ethics Committee
of the University of Tartu and all patients provided signed
informed consent.
Materials and procedure
The demographic and social data (age, gender, urban/
rural living, marital status, living alone/with others, level
of education) and data regarding PD (age at disease on-
set, disease duration, clinical subtype) and other clinical
factors (levodopa equivalent daily dose, duration of levo-
dopa treatment, comorbidities) were recorded using
specially developed case report forms. Disease sub-
types were based upon the most prevalent symptom
during standard neurological examinations: (1) tremor;
(2) bradykinesia-hypokinesia; (3) postural instability and
gait disorder.
To evaluate HRQoL, PDQ-39—a validated, disease-
specific quality of life instrument—was used [12]. The
higher the PDQ-39 summary index (SI) score, the lower
the perception by patients of their quality of life. An
Estonian version of the PDQ-39 has been shown as a
reliable instrument [13].
Non-motor PD symptoms were identified using Part I
of the MDS-UPDRS. In 2008 the Movement Disorder
Society (MDS) adopted a new, validated version of the
MDS-UPDRS, which included several significant updates
in comparison with the previous version, including new
non-motor symptoms of PD [10]. The Estonian version
of the MDS-UPDRS was translated, validated and of-
ficially approved in 2011 by the MDS Translation
Program for non-English official versions. The MDS-
UPDRS Part IA contains questions regarding a number
of neuropsychiatric symptoms and is completed by the
interviewer; Part IB consists of questions on non-motor
symptoms and is answered by the patient or caregiver.
Other parts of the MDS-UPDRS were used: Part II
regards the motor experiences of daily living as assessed
by the patient or caregiver; Part III assesses motor symp-
toms based on an objective neurological examination;
Part IV regards motor complications and is completed by
the interviewer.
The clinical stage of a patient’s PD was assessed using
the Hoehn and Yahr scale (HY) [14] and their level of
disability by the Schwab and England Activities of
Daily Living Scale (SE-ADL) [15]. The HY scale ranges
from 1 (unilateral involvement of the body) to 5
(wheelchair bound or bedridden). The SE-ADL scale
ranges from 0 % (completely dependent and bedrid-
den) to 100 % (completely independent). For assess-
ment of depression the Beck Depression Inventory
(BDI) was used [16], whereby a score of ≥14 is indica-
tive of depression [17]. Cognitive impairment was
measured using the Mini Mental State Examination
(MMSE) [18], whereby a score of ≤24 is evidence of
cognitive impairment.
Statistical analysis
PDQ-39 SI measures of HRQoL were calculated accord-
ing to its scoring algorithm [12, 19]. Prevalence of non-
motor symptoms was based on scores ≥1, which denoted
the presence of a symptom. Student’s t-test and z-test
were applied for comparing socio-demographic and
clinical outcomes between men and women. The non-
parametric Mann–Whitney and Kruskal-Wallis tests were
used to compare PDQ-39 SI scores between the groups.
Spearman’s rank correlation coefficients were calculated to
assess associations between variables. Correlation coeffi-
cients were interpreted as very weak (r = 0–0.19),
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weak (r = 0.20–0.39), moderate (r = 0.40–0.59), strong
(r = 0.60–0.79) or very strong (r = 0.80–1.00).
A multiple linear regression analysis—based on a back-
ward elimination approach—was conducted to deter-
mine the factors that contribute to HRQoL in persons
with PD. PDQ-39 SI was used as a dependent variable.
The R2 statistic was used to determine the proportion of
variance explained by the predictors. The level of statis-
tical significance was set at p < 0.05. Statistical analysis
was performed using STATA version 12.0 (StataCorp LP,
College Station, TX, USA) and SPSS version 20.0 (IBM
Corporation, Armonk, NY, USA).
Results
Patient characteristics
Demographic and clinical characteristics of the study
population are given in Table 1. Men were slightly
younger than women (72.1 and 75.6 years respectively,
p = 0.0014), which reflects the shorter life expectancy of
men in Estonia. No significant differences in terms of
PD onset age, disease duration, HY stage, SE-ADL stage
or MMSE performance were found between men and
women. The mean BDI depression score was signifi-
cantly higher in women compared to men (17.1 and 12.3
respectively, p = 0.0001). A significantly higher rate of
men compared to women were: married (71.4 % and
32.5 % respectively, p < 0.0001); lived with their
spouse and or children (89.5 % and 60.1 % respectively,
p < 0.0001). There were more widows among female
than male patients (48.5 % and 17.1 % respectively,
p = 0.02). Women had a higher mean number of co-
morbidities compared to men (2.23 and 1.86 respectively,
p = 0.0124), including a significantly higher rate of
cardiovascular diseases (99.4 % and 89.6 % respectively,
p < 0.0001). Mean scores of PDQ-39 domains are pre-
sented in Fig. 1. In persons with PD, mobility (mean score
53.1) was the most negative HRQoL domain and social
support (mean score 13.17) the least negative domain.
Prevalence of non-motor symptoms
Among the 268 patients screened, 99.6 % complained of
at least one non-motor symptom. There were a mean
number of 6.7 non-motor symptoms (SD 2.5) per patient
of the 13 symptoms included in the MDS-UPDRS Part I.
The most frequent non-motor symptoms were cognitive
impairment, night time sleep disorders, bladder disor-
ders, fatigue, pain, daytime sleepiness and depression.
Hallucinations and impulsive compulsive disorders
(ICDs) were the most infrequently reported non-motor
symptoms. We did not find a statistically significant dif-
ference between mean BDI scores for persons with PD
and with ICDs, and persons with PD and without ICDs
(mean score 19.1 and 15.1, respectively, p = 0.254).
Prevalence of non-motor symptoms is given in Table 2.
PDQ-39 and socio-demographic factors affecting HRQoL
The results of univariate analysis of socio- demographic
and clinical parameters and mean scores of PDQ-39 SI
in persons with PD are shown in Table 3. Emotional
well-being and bodily discomfort affected women signifi-
cantly more than men. Being over 65 years old was asso-
ciated with lower mobility: being younger was associated
Table 1 Characteristics of the patients
Variable Value Range
Age a 74.2 yr (±8.8) 47-96
Disease onset age a 66.8 yr (±10.1) 35-88
Duration of disease a 7.6 yr (±5.9) 1-35
HY ≥3, n (%) 164 (62.6 %)
SE-ADL ≤75 %, n (%) 139 (53.3 %)
MMSE ≥25, n (%) 197 (76.7 %)
BDI ≥14, n (%) 134 (52.1 %)
MDS-UPDRS
MDS-UPDRS Part I 12.52 (6.79) 0-38
MDS-UPDRS Part II 18.2 (8.4) 1-48
MDS-UPDRS Part III 46.3 (18.3) 10-106
MDS-UPDRS Part IV 1.3 (3.4) 0-18
Clinical subtypes
Tremor dominant 118 (44 %)
Hypokinetic-rigid dominant 77 (28.7 %)
Postural instability and gait disturbance
dominant
73 (27.3 %)
Levodopa equivalent dose per day a 427.5 mg (±231.6) 100-1200
Duration of levodopa treatment a 3.9 yr (±5.03) 0.1-23
Marital status, n (%)
Single 20 (7.4 %)
Married 128 (47.8 %)
Divorced 23 (8.6 %)
Widowed 97 (36.2 %)
Living status, n (%)
With a spouse 137 (51,1 %)
With children 55 (20,5 %)
Alone 66 (24.6 %)
Nursery home 10 (3.8 %)
Education, n (%)
Primary
Secondary 104 (38.8 %)
Higher 95 (35.5 %)
69 (25.7 %)
a Mean (standard deviation)
Abbreviations: HY, Hoehn and Yahr stage; SE-ADL, Schwab and England Activities
of Daily Living Scale; MMSE, Mini Mental State Examination; BDI, Beck Depression
Inventory; MDS-UPDRS, Movement Disorders Society Unified Parkinson’s Disease
Rating Scale
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with higher stigmatisation. Marital status was not signifi-
cantly associated with PDQ-39 scores. Emotional well-
being was significantly related to living status, i.e.
patients living alone had lower emotional well-being
compared to patients living with their spouse and/or
children. Education did not significantly influence over-
all HRQoL. People who had undergone no more than
primary level education were significantly more affected
in the domain of mobility.
PDQ-39 and clinical factors affecting HRQoL
Overall HRQoL was significantly lower in patients with
depression, which had an impact on all the PDQ-39
domains. Longer disease duration, a HY stage ≥3 and
SE-ADL ≤75 % were associated significantly with lower
overall HRQoL and affected most of the PDQ-39 do-
mains. Patients with cognitive impairment had lower
overall HRQoL and were significantly more adversely
affected in the domains of mobility, activities of daily liv-
ing and communication.
By clinical PD subtype, the group with postural in-
stability and gait disturbance had the lowest overall
HRQoL (compared to the tremor and hypokinetic-rigid
clinical subtypes). Out of PDQ-39 domains, mobility and
activities of daily living had the lowest outcome.
Correlation analysis between PDQ-39 SI and
socio-demographic and clinical factors
PDQ-39 SI correlated significantly with higher MDS-
UPDRS Part II, BDI and MDS-UPDRS Part IB scores.
All non-motor symptoms—except ICDs—correlated sig-
nificantly with PDQ-39 SI. All correlations between
PDQ-39 and the other characteristics of PD are shown
in Table 4.
Multiple linear regression model of PDQ-39 SI
Potential predictors were determined based on the
previous correlation analysis. Duration of disease,
HY, SE-ADL, MMSE, BDI, MDS-UPDRS Parts IA,
IB, II-IV, duration of levodopa treatment, daily dose
of levodopa, postural instability and gait disorder or
tremor dominated disease types were identified as in-
dependent variables using univariate regression ana-
lysis. Multiple linear regression analysis was then
performed on all the independent variables found
during the previous univariate regression analysis and
common epidemiological variables, i.e. age and gender.
The final model (Table 5) explained 59.9 % (adjusted R2,
p < 0.0001) of the variance of PDQ-39 SI, with BDI,
MDS-UPDRS II, MDS-UPDRS Part IB significant
Fig. 1 Mean values of PDQ-39 domains. HRQoL was assessed by using the PDQ-39. PDQ-39 is composed of 39 items grouped in 8 subscales:
(1) mobility, (2) activities of daily living, (3) emotional well-being, (4) stigma, (5) social support, (6) cognition, (7) communication, and bodily discomfort.
The PDQ-39 SI is an overall score calculated from these domains, with 0 indicating the best HRQoL and 100 the worst
Table 2 Prevalence of non-motor symptoms
Non-motor symptoms N %
Cognitive impairment 199 74.3 %
Nighttime sleep problems 192 71.6 %
Urinary problems 192 71.6 %
Fatigue 184 68.7 %
Pain 172 64.2 %
Daytime sleepiness 166 61.9 %
Depressed mood 163 60.8 %
Constipation problems 156 58.2 %
Anxious mood 151 56.3 %
Lightheadedness on standing 140 52.2 %
Apathy 122 45.7 %
Hallucinations and psychosis 37 13.8 %
ICDs 21 7.8 %
Abbreviations: ICDs, impulse control disorders
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predictors and depression the most significant pre-
dictor of HRQoL.
Discussion
The purpose of this study was to investigate factors that
may contribute to low HRQoL in persons with PD. We
found that the main clinical determinants of low HRQoL
in persons with PD were depression and the high
Table 3 PDQ-39 associations with demographic and clinical
features













With a spouse 30.6 (15.4)
With children 31.5 (17.1)
Alone 33.5 (13.5)





Clinical subtypes 0.0017; 1vs 3
Tremor 28.6 (14.9)
Hypokinetic-rigid 30.5 (14.4)
Postural instability and gait disturbance 37.3 (15.3)
Disease duration 0.00010; 1 vs 3
≤5 yr 26.5 (13.0)
6-10 yr 32.1 (16.1)













a Mean (standard deviation)
Abbrevations: HY, Hoehn and Yahr stage; SE-ADL, Schwab and England
Activities of Daily Living Scale; MMSE, Mini Mental State Examination;
BDI, Beck Depression Inventory
Table 4 Spearman’s correlation analysis of clinical variables and
PDQ-39 SI scores
Variable Coefficient p value
Disease duration 0.30 <0.0001
Clinical subtypes
Tremor dominant -0.17 0.006
Hypokinetic-rigid dominant -0.05 0.449





Daily dose of levodopa 0.32 <0.0001
Duration of levodopa treatment 0.23 0.0001
Number of comorbidities 0.07 0.5041
MDS-UPDRS Part I – Non-motor experiences
of daily living
0.62 <0.0001
MDS-UPDRS Part IA 0.51 <0.0001
MDS-UPDRS Part IB 0.61 <0.0001
Cognitive impairment 0.38 <0.0001
Hallucinacions and psychosis 0.24 0.0001
Depressed mood 0.35 <0.0001
Anxious mood 0.29 <0.0001
Apathy 0.33 <0.0001
ICDs 0.07 0.2490
Nighttime sleep problems 0.29 <0.0001
Daytime sleepiness 0.35 <0.0001
Pain and other sensations 0.38 <0.0001
Urinary problems 0.30 <0.0001
Constipation problems 0.13 0.0281
Lightheadedness on standing 0.34 <0.0001
Fatigue 0.44 <0.0001
MDS-UPDRS Part II – Motor experiences of daily
living
0.65 <0.0001
MDS-UPDRS Part III – Motor examination 0.46 <0.0001
MDS-UPDRS Part IV – Motor complications 0.22 0.0003
Abbrevations: PDQ-39, The Parkinson’s Disease Questionnaire; SI, summary index
score; HY, Hoehn and Yahr stage; SE-ADL, Schwab and England Activities of Daily
Living Scale; MMSE, Mini Mental State Examination; BDI, Beck Depression
Inventory; MDS-UPDRS, Movement Disorders Society Unified Parkinson’s Disease
Rating Scale; ICDs, Impulse control disorders
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burdens of motor and non-motor aspects of daily living.
None of the investigated socio-demographic variables
significantly associated with HRQoL.
Depression has an average prevalence of about 40 %
among persons with PD [20] and is a recognized pre-
dictor of low HRQoL. As previous studies [5, 8], we
found depression to be one of the most significant deter-
minant of HRQoL. A study by Leentjens et al. [21] dem-
onstrated that the risk factors in the general population
for depression—such as older age, female gender, som-
atic comorbidities, and personal and family history of
depression—also predict depression in persons with PD.
In our sample the prevalence of depression in female pa-
tients was significantly higher than in male patients
(58 % and 43 % respectively, p = 0.0189). In addition to
BDI, depression was more often reported by women
according to Part IA of the MDS-UPDRS. Studies exam-
ining gender differences regarding prevalence of depres-
sion have yielded inconsistent results. While van der
Hoek et al. [22] found no difference in the prevalence of
depression in male and female persons with PD, Solla
et al. [23] found prevalence of depression significantly
higher in female persons with PD. The reason why
women are more disposed to depression might partly be
explained by the greater exposure of competing risk fac-
tors, as suggested by Sonnenberg et al. [24] who demon-
strated this association in a study on gender differences
for depression in the elderly of a general population:
controlling for age, comorbid somatic disease, and a
number of other risk factors reduced the relative risk of
depression in women by more than a half. The female
patients in our study were slightly older than the male
patients, were more often widowed and had a higher
mean number of comorbidities. Men in our cohort were
significantly more often married and lived together with
their wife and or children. Based on the studies by
Sonnenberg et al., it could be assumed that controlling
for several factors associated with social and health sta-
tus might reduce the relative risk of depression in female
persons with PD.
In recent years there has been increasing evidence sug-
gesting that the impact of non-motor symptoms on
HRQoL is more important than the impact of motor fea-
tures [8, 9]. Similar to previous studies, our study re-
vealed that HRQoL was significantly lower with higher
loads of non-motor symptoms. All non-motor symptoms
correlated significantly with PDQ-39 SI, except the
features of ICDs: a heterogeneous group of pathological
behaviours associated with dopamine replacement treat-
ment that include pathological gambling, compulsive
sexual behaviour, compulsive shopping, and binge eat-
ing, together with pounding and the addiction-like com-
pulsive use of dopamine replacement therapy [25]. A
case study by Voon et al. indicated that patients with
ICDs have more depressive symptoms [26]. We did not
find a statistically significant difference between mean
BDI scores for persons with PD and with ICDs (based
on positive item 1.6 in MDS-UPDRS Part IA), and per-
sons with PD and without ICDs. Reducing the dosage or
discontinuing the administration of dopaminergic ago-
nists or substituting another drug from this group is a
frequently effective therapeutic measure [25, 27]. Only a
few studies on the impact of ICDs on HRQoL have been
published and some found controversial results, i.e. ICDs
as a predictor of lower HRQoL [28, 29], but in other
studies [30] ICDs did not affect HRQoL. The current
study did not reveal a negative impact of ICDs on qual-
ity of life. Our finding is supported by a study by Ondo,
where only 18 % of patients with increased impulsivity
felt that the change was deleterious [30]. Our daily clin-
ical practice suggests that ICDs cause considerable dis-
tress to patients’ families or caregivers, but the patients
themselves are not that annoyed by these behaviours.
Out of the 268 patients screened in our study, 7.8 %
(n = 21) complained of ICDs. It could be assumed
that at least one reason why ICDs did not correlate
significantly with HRQoL is that the pathological be-
haviours were relatively mild. About half (52 %) of
these patients reported only slight problems with behav-
ioural disturbances and it could be that the problems did
not yet affect their social and occupational functioning.
Dependency in activities of daily living as assessed
using the SE-ADL scale and disability in the perform-
ance of daily living experiences as measured by the pre-
vious version of the UPDRS Part II, have been found to
be significant contributors to HRQoL [5]. In a recently
published study by Rodriguez-Blazquez et al. [31], who
used the MDS-UPDRS Part II, a significant negative
association between the more advanced disability and
Table 5 Predictors of HRQoL in stepwise multiple regression
analysis
Model Unstandardized coefficients p value
B SE
BDI 0.734 0.089 0.0001
MDS-UPDRS Part IB 0.603 0.201 0.003
MDS-UPDRS Part II 0.546 0.127 0.0001
MDS-UPDRS Part III 0.067 0.050 0.182
Age -0.124 0.077 0.108
Duration of the disease 0.251 0.184 0.175
Duration of levodopa treatment -0.339 0.211 0.109
Multiple R2 = 0.611
Adjusted R2 = 0.599
HRQoL, health-related quality of life; SE, standard error; BDI, Beck depression
inventory; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease
Rating Scale
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HRQoL occurred. The current study demonstrated that
disability evaluated by SE-ADL and MDS-UPDRS Part II
significantly contributed to lower HRQoL. However,
motor symptoms (MDS-UPDRS Part III) were not an in-
dependent predictor of HRQoL. Even though for anti-
parkinsonian treatment Part III with motor assessments
is of high importance, it can be seen that for HRQoL,
the self-assessment of non-motor symptoms and ability
to perform daily activities have more impact.
An axial impairment has been shown to be associated
with reduced HRQoL in persons with PD [6]. We found
that patients with postural instability and gait disorder
dominance had significantly lower overall HRQoL com-
pared to patients with tremor dominance or hypokinetic-
rigid dominance; however, in multiple regression analysis
it did not appear to be an independent predictor of
HRQoL. Neither was HY stage found to be an independ-
ent predictor, though patients with more severe PD
(HY ≥3) had lower HRQoL than patients with milder
PD. The results of the multiple regression analysis
were concordant, as higher HY stages reflected an
axial involvement with balance and gate impairments.
Persons with PD in general, but particularly in patients
with the postural instability and gait disorder, are likely
to become less able to move around inside their homes
and out in the community. They also become more
prone to falls as the disease progresses. Regular physical
exercise is associated with higher HRQoL, mobility, phys-
ical function, slowing the progression of the disease,
lower caregiver burden, and less cognitive decline [32].
In view of this, patients with the postural instability
and gait disorder may benefit most from education on
using rehabilitation activities (e.g. physical exercise,
physiotherapy) and assistive devices (e.g. reaching
aids). Therefore, in addition to pharmacological treat-
ment, the management of PD should include rehabili-
tative care, which helps to maintain patients’ ability to
participate in daily living activities and avoid the de-
cline of HRQoL.
In our study socio-demographic characteristics includ-
ing age, gender, urban/rural living, level of education,
marital status and living alone/with others, did not sig-
nificantly affect overall HRQoL. However, we found sev-
eral associations between these factors and domains of
PDQ-39. Women received lower scores for emotional
well-being and bodily discomfort, which is in accordance
with the study by Carod-Artal et al. [5]. As regards to
patients’ living status, those who lived alone received
lower scores for emotional well-being compared with
patients who lived with others. Another study by Winter
et al. showed that patients living alone had worse
HRQoL than patients living with somebody [7]. Our
results did not reveal any statistically significant difference
in HRQoL among patients with different educational
backgrounds, whereas greater number of years in educa-
tion was found to be associated with higher HRQoL in
a study by Carod-Artal et al. [5]. Klepac et al. [33]
found that rural patients had lower overall HRQoL,
with most of the domains of PDQ-39 affected. In con-
trast, the results of our study suggest that living area
is not associated with overall HRQoL. Moreover, our
results showed that patients living in rural areas had
significantly less stigmatization and better social sup-
port than patients living in urban areas.
The study has some methodological limitations that
ought to be recognized and taken into account when
interpreting the findings. The analysis was based on clin-
ical data collected at a single point in time; therefore,
any pattern of progression of the disease could not
be estimated. Also, we cannot exclude the possibility
that some of the variables, such as gender (female
patients outnumbered male patients) or stage of dis-
ease (62.6 % of patients had HY ≥3) could have in-
fluenced the results found.
The strength of the study was the relatively large sam-
ple of persons with PD, which included institutionalised
and severely ill patients, and thus was representative of
the PD population as a whole. The study participants
were also evaluated with a wide range of clinimetric
properties that covered motor, non-motor, functional,
cognitive and emotional aspects.
Conclusion
The results of our study suggest that both non-motor
and motor aspects affect the daily living and HRQoL of
persons with PD. Our results are consistent with other
studies that have suggested depression to be the stron-
gest predictor of HRQoL in persons with PD and there-
fore depression should be recognized early and treated
appropriately. Attention should also be paid to other
common non-motor symptoms that may require a
multidisciplinary approach, such as cognitive impair-
ment, sleep problems, urinary problems and fatigue. A
novel observation of this study was that ICDs were the
only non-motor symptom not associated with lower
HRQoL. Further research in this setting is planned to
explore the role of behavioural disturbances in HRQoL
among persons with PD.
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